In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Novo Nordisk, Schering end Prandin co-promotion

Executive Summary

Novo Nordisk and Schering-Plough agreed to jointly launch and promote Novo's Prandin (repaglinide), an oral antidiabetic agent for the treatment of Type II diabetes, and Novo Nordisk's full range of insulin products and devices, in the US.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • R&D and Marketing (Licensing)

Related Companies